- Trial Phase
- Phase 2B/3
- Time to Market
- If pivotal trial succeeds, potential accelerated NDA filing as early as 2027, with potential approval 2028-2029.
- Why 7/10
- The next hard, dated catalyst is the full Phase 2B/3 MIRACLE Part A data readout (n=75-90) expected H2 2026 (the second 45-patient cohort unblinding). This is the company's lead and near-only program — the entire ~$17M market cap rides on confirming the signal seen in the first 45 patients. Cash only runs into Q3 2026, adding existential pressure.
Watch for the second 45-patient Part A unblinding in H2 2026. The first 45-patient cut showed a compelling numerical 3x CR rate (43%/36% vs 12%) but missed statistical significance due to small sample — investors sold hard. A statistically significant result in the full Part A would remove the doubt and could drive a re-rate, but the company will almost certainly need to dilute to fund through Part B.
Price Chart
Executive Summary
Annamycin (naxtarubicin) is Moleculin Biotech's lead drug candidate — a next-generation liposomal anthracycline being developed primarily for relapsed/refractory acute myeloid leukemia (AML). Its key selling point is a potentially clean cardiac safety profile, differentiating it from all currently approved anthracyclines whose use is capped by cumulative heart damage. On June 30, 2026, the company reported positive interim data from 45 patients in the pivotal MIRACLE trial showing a 3x higher complete remission rate (43% and 36% vs 12% control), but the data did not reach statistical significance in this small sample, causing the stock to drop ~25%. The full Part A data (~90 patients) is due in H2 2026 and will be the defining near-term catalyst. With cash runway only into Q3 2026 and a ~$17M market cap, this is a high-risk binary setup.
How It Works
Annamycin is a next-generation version of a classic class of chemotherapy drugs called anthracyclines (which include doxorubicin and daunorubicin). These drugs work by inserting into cancer cell DNA and jamming the machinery that cells use to copy and repair their DNA, ultimately causing the cancer cell to self-destruct. Annamycin is formulated in a liposome (a fat bubble) to more effectively deliver the drug to cancer cells. Its key innovation is that it appears to avoid the permanent heart damage that limits how much traditional anthracycline a patient can receive over a lifetime — meaning patients can potentially get higher, more effective doses without their heart giving out.
Trial Status
The adaptive Phase 2B/3 MIRACLE trial is actively enrolling in Part A (75-90 patients, 1:1:1 randomization to Annamycin 190 mg/m² + HiDAC, 230 mg/m² + HiDAC, or placebo + HiDAC). Results from the first 45 patients were reported June 30, 2026. The second cohort of ~45 patients is expected to be fully recruited in Q3 2026 with unblinding in H2 2026. Part B would then add ~222 more patients, with final analysis expected in 2028.
The Two-Sided Case
Upcoming Catalysts
- Full Part A data readout (n=75-90) of the MIRACLE Phase 2B/3 trial — expected H2 2026
- Completion of Part A enrollment (Q3 2026) and dose selection for Part B
- Potential financing / capital raise event given cash runway into Q3 2026
- Update from soft tissue sarcoma lung metastases program (Phase 1B/2)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Moleculin Biotech, Inc. 8-K MBRX ·Originating report